Update of the management of chronic psoriasis: New approaches and emerging treatment options

Clinical, Cosmetic and Investigational Dermatology

Volumn 3, Issue , 2010, Pages 25-37

  Laws, Philip M ^a   Young, Helen S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biological therapy; Management; Psoriasis; Treatment

Indexed keywords

ABT 874; ADALIMUMAB; AIN 457; ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BRIAKINUMAB; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CERTOLUZIMAB PEGOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FEZAKINUMAB; FUMADERM; FUMARIC ACID DERIVATIVE; GOLIMUMAB; INFLIXIMAB; JANUS KINASE 3 INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RETINOID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VOCLOSPORIN;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL THERAPY; CANCER RISK; CHILL; CHRONIC PLAQUE PSORIASIS; CHRONIC PSORIASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHRODERMIC PSORIASIS; GASTROINTESTINAL SYMPTOM; GENERAL PUSTULAR PSORIASIS; GOLD STANDARD; HEART FAILURE; HEPATITIS B; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; IMMUNIZATION; INFECTIOUS COMPLICATION; INVERSE PSORIASIS; KIDNEY DYSFUNCTION; LISTERIOSIS; LIVER BIOPSY; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NAIL DISEASE; NAUSEA; OPPORTUNISTIC INFECTION; PHENOTYPE; PHOTOTHERAPY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS GUTTATA; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SKIN DEFECT; SYSTEMIC THERAPY; T LYMPHOCYTE; TUBERCULOSIS; TYPE 1 CHRONIC PLAQUE PSORIASIS; UNSPECIFIED SIDE EFFECT; VOMITING; VON ZUMBUSCH PSORIASIS;

EID: 77953413433     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.
2. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450-456.
3. de Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:40-47.
4. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846-850.
5. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407.
6. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol. 1996;132:717-718.
7. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627-632.
8. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999;26: 1752-1756.
9. McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol. 2009;21:340-347.
10. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4:441-447.
11. Gottlieb AB, Mease PJ, Mark Jackson J, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat. 2006;17:279-287.
12. Brockbank JE, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:88-90.
13. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78.
14. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673.
15. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805-821.
16. Brophy S, Taylor G, Blake D, et al. The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis. J Rheumatol. 2003;30:2054-2058.
17. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99:469-475.
18. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-85.
19. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
20. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/beta-methasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389-393.
21. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154:1155-1160.
22. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217:321-328.
23. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59:455-463.
24. Lebwohl M, Freeman AK, Chapman MS et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51:723-730.
25. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51:731-738.
26. Berger TG, Duvic M, Van Voorhees AS et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818-823.
27. Tham SN, Gange RW, Parrish JA. Ultraviolet-B treatment of psoriasis in patients with concomitant vitiligo. Arch Dermatol. 1987;123: 26-27.
28. Yones SS, Palmer RA, Garibaldinos TT, et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis:efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142:836-842.
29. Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156:258-262.
30. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40-55.
31. Sandhu K, Kaur I, Kumar B, et al. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis:a study from north India. J Dermatol. 2003;30:458-463.
32. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658-665.
33. Flytstrom I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis:effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008;158:116-121.
34. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
35. Roenigk HH, Jr., Auerbach R, Maibach H, et al. Methotrexate in psoriasis:consensus conference. J Am Acad Dermatol. 1998;38: 478-485.
36. Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate:a multicentre audit and health economic analysis. Br J Dermatol. 2005;152: 444-450.
37. Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients:Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int. 2007;27:639-645.
38. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a. 2-year cohort study. J Am Acad Dermatol. 2001;44:643-651.
39. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a. 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol. 1999;141:283-291.
40. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol. 1998;139:88-95.
41. Thaci D, Brautigam M, Kaufmann R, et al. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology. 2002;205:383-388.
42. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis:a randomized controlled trial. Br J Dermatol. 2001;145:438-445.
43. Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice:an international consensus statement. Br J Dermatol. 2004;150 Suppl 67:11-23.
44. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36: 423-432.
45. Mrowietz U, Farber L, Henneicke-von Zepelin HH, et al. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis:results of a multicenter study. German Multicenter Study. J Am Acad Dermatol. 1995;33:470-475.
46. Lowe NJ, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24:591-594.
47. Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf. 2005;4:129-138.
48. Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemo-therapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25:682-684.
49. Lebwohl M, Drake L, Menter A, et al. Consensus conference:acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45:544-553.
50. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126: 453-459.
51. Diaz BV, Lenoir MC, Ladoux A, et al. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem. 2000;275:642-650.
52. Schweckendiek W. [Treatment of psoriasis vulgaris.]. Med Monatsschr. 1959;13:103-4.
53. Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383-1388.
54. Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003;149:363-369.
55. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters:results of a prospective multicentre study. German Multicentre Study. Br J Dermatol. 1998;138:456-460.
56. Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis:a retrospective review of 58 cases. Br J Dermatol. 2005;153:549-551.
57. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. 2005. Br J Dermatol. 2005;153:486-497.
58. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation:monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58:94-105.
59. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis. 2009. Br J Dermatol. 2009;161:987-1019.
60. Avery RK. Vaccination of the immunosuppressed adult patient with rheumatologic disease. Rheum Dis Clin North Am. 1999;25:567-584.
61. Avery RK. Immunizations in adult immunocompromised patients:which to use and which to avoid. Cleve Clin J Med. 2001;68:337-348.
62. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis:the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65:191-194.
63. Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007;46:608-611.
64. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept:practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin. 2004;22: 449-459.
65. Krueger GG, Elewski B, Papp K, et al. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;54:S112-119.
66. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603.
67. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis:safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
68. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis:double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29-35.
69. Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis:a. 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158:1345-1349.
70. Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495-501.
71. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial. Lancet. 2004;363:675-681.
72. Cohen JD, Zaltni S, Kaiser MJ, et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann Rheum Dis. 2004;63:209-210.
73. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-251.
74. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis:a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374.
75. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over. 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31e1-15.
76. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis:a randomized controlled trial. Br J Dermatol. 2006;154:1161-1168.
77. Reich K, Nestle FO, Wu Y, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17:381-386.
78. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis:A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
79. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
80. Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75.
81. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis:meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:513-526.
82. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis:a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol. 2006;54: S92-S100.
83. Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527-536.
84. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46: 2565-2570.
85. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48: 319-324.
86. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078-1082.
87. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686-687.
88. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45: 507-539.
89. Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416-2420.
90. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk:mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155.
91. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-626.
92. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
93. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159:1217-1228.
94. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-811.
95. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 2008;58:667-677.
96. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-580.
97. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54:S139-S142.
98. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703.
99. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64: 1421-1426.
100. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295: 2275-2285.
101. Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009;68:1240-1246.
102. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy:is there a need for more comprehensive screening procedures? Arthritis Rheum. 2009;61:801-812.
103. Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005;141:861-864.
104. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy:analyses from a large US observational study. Arthritis Rheum. 2007;56:2886-2895.
105. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-255.
106. Krueger GG. Clinical response to alefacept:results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17 Suppl 2: 17-24.
107. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of. 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
108. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intra-muscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
109. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis:results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1638-1645.
110. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
111. Joshi A, Bauer R, Kuebler P, et al. An overview of the pharma-cokinetics and pharmacodynamics of efalizumab:a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 2006;46: 10-20.
112. Guttman-Yassky E, Vugmeyster Y, Lowes MA, et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol. 2008;128: 1182-1191.
113. Ortonne JP, Shear N, Shumack S, et al. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients:results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol. 2005;5:13.
114. Dubertret L, Sterry W, Bos JD, et al. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-181.
115. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425-433.
116. Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006;45:605-614.
117. Pariser DM, Gordon KB, Papp KA, et al. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis:results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005;9:303-312.
118. Papp KA, Caro I, Leung HM, et al. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg. 2007;11:57-66.
119. Pugashetti R, Koo J. Efalizumab discontinuation:a practical strategy. J Dermatolog Treat. 2009;20:132-136.
120. Major EO. Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies. Annu Rev Med. 2010;61:35-47.
121. Robertson MJ, Ritz J. Interleukin. 12:Basic Biology and Potential Applications in Cancer Treatment. Oncologist. 1996;1:88-97.
122. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type. 17 helper T cells. N Engl J Med. 2009;361:888-898.
123. Blauvelt A. T-helper. 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128: 1064-107.
124. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-592.
125. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX. 1). Lancet. 2008;371: 1665-1674.
126. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX. 2). Lancet. 2008;371: 1675-1684.
127. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin. 12/23 monoclonal antibody, for psoriatic arthritis:randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-640.
128. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368-2376.
129. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy:results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905-2912.
130. Hyrich KL, Symmons DP, Watson KD, et al. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006;54: 2701-2702.
131. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis:a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002;41:1133-1137.
132. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov. 2008;7:641-642.
133. Gladman D, Kavanaugh, A, McInnes, I, et al. Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis:Nail, enthesitis, and dactylitis response in the randomized, placebo controlled, GO-REVEAL study. (Abstract) Ann Rheum Dis. 2008; 67 (Suppl II).
134. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin. 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase. 2 trial. Arch Dermatol. 2008;144:200-207.
135. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-651.
136. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496-509.
137. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;12495:1022-10, e1-395.
138. Abdelnoor AM. Patented small molecules against psoriasis. Expert Opin Ther Pat. 2009;19:1057-1071.
139. Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis:a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1337-1342.
140. Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med. 2004;10:532-541.
141. Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal. 2009;5:107-115.
142. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129:2299-2302.